Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
LUMO Lumos Pharma
5.150
+0.055+1.08%
Post Mkt Price
5.1500.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
497K 3,930.00% 403K 111K 36.90% 230K
Operating revenue
-- 497K 3,930.00% 403K -- 111K 36.90% 230K
Cost of revenue
Gross profit
Operating expense
7.34% 8.05M -4.00% 8.33M -8.99% 7.84M 19.29% 31.58M
Selling and administrative expenses
15.75% 3.92M -19.27% 3.68M -8.49% 3.62M -11.20% 15.33M
-General and administrative expense
15.75% 3.92M -19.27% 3.68M -8.49% 3.62M -11.20% 15.33M
Research and development costs
0.41% 4.13M 12.93% 4.65M -9.42% 4.22M 76.47% 16.25M
Operating profit
-0.71% -7.55M 8.54% -7.92M 10.28% -7.73M -19.18% -31.35M
Net non-operating interest income expense
14,500.00% 292K 3,600.00% 74K 114.71% 5K -94.00% 12K
Non-operating interest income
14,500.00% 292K 3,600.00% 74K 66.67% 5K -94.00% 12K
Non-operating interest expense
-- 0 -- 0 -- 0 -- --
Other net income (expense)
0.00% 7K 175.00% 6K -70.00% 6K -95.84% 269K
Other non- operating income (expenses)
0.00% 7K 175.00% 6K -70.00% 6K -95.84% 269K
Income before tax
3.17% -7.25M 9.53% -7.84M 10.55% -7.72M -58.21% -31.07M
Income tax
95.45% -636K
Net income
3.17% -7.25M 9.53% -7.84M 10.55% -7.72M -437.35% -30.43M
Net income continuous Operations
3.17% -7.25M 9.53% -7.84M 10.55% -7.72M -437.35% -30.43M
Minority interest income
Net income attributable to the parent company
3.17% -7.25M 9.53% -7.84M 10.55% -7.72M -437.35% -30.43M
Preferred stock dividends
Other preferred stock dividends
0
Net income attributable to common stockholders
3.17% -7.25M 9.53% -7.84M 10.55% -7.72M -381.94% -30.43M
Basic earnings per share
4.44% -0.86 5.05% -0.94 11.54% -0.92 -292.47% -3.65
Diluted earnings per share
4.44% -0.86 5.05% -0.94 11.54% -0.92 -292.47% -3.65
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
CEO: Mr. Richard J. Hawkins
Market: NASDAQ
Listing Date: 11/11/2011
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist